首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Cancer Communications

Cancer Communications杂志,由Wiley出版,于2018年创刊,Monthly,出版语言English,ISSN:2523-3548,E-ISSN:2523-3548。

投稿咨询
Cancer Communications
Cancer Communications
Cancer Communications
SCI SCIE

杂志介绍

JCR分区
Q1
中科院分区
1区
影响因子
28.4
CiteScore
40.3
期刊收录
SCI、SCIE

Cancer Communications(中文译名:《癌症通讯》),ISSN:2523-3548,EISSN:2523-3548,是Wiley出版的国际性学术期刊,创刊于2018年,以Monthly形式稳定发行,2026年总发文量约49篇。该刊采用OA开放访问,学科归属为Biochemistry, Genetics and Molecular Biology - Cancer Research。该刊是医学、肿瘤学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达28.4,2025年期刊CiteScore为40.3,2025年期刊自引率约0.7%,在中科院期刊分区体系中位列医学大类1区TOP 期刊,在所属学科领域具备高学术影响力与国际认可度。Cancer Communications长期聚焦医学、肿瘤学及相关产业的技术应用前沿,平均审稿周期4 Weeks,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、肿瘤学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,CHINA MAINLANDUSA、Singapore、England、GERMANY (FED REP GER)、Italy、Japan等为核心发文国家与地区;SUN YAT SEN UNIVERSITYSTATE KEY LAB ONCOLOGY SOUTH CHINA、CHINESE ACADEMY OF MEDICAL SCIENCES - PEKING UNION MEDICAL COLLEGE、PEKING UNIVERSITY、TIANJIN MEDICAL UNIVERSITY、FUDAN UNIVERSITY、SHANGHAI JIAO TONG UNIVERSITY等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
ONCOLOGY 肿瘤学
1区
是 否

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
ONCOLOGY 肿瘤学
1区
是 否

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
ONCOLOGY 肿瘤学
2区
否 否

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q1 11 / 333

96.8

学科:ONCOLOGY SCIE Q1 14 / 333

95.95

2023-2024年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q1 14 / 322

95.8

学科:ONCOLOGY SCIE Q1 16 / 322

95.19


中国学者近期发文

1
Camrelizumab Plus Nab-paclitaxel in Patients with Previously Treated Advanced Urothelial Carcinoma: A Multicenter Phase II Stud

Author:Li, Haifeng; Chen, Meiting; Huang, Riqing; Rong, Qixiang; Hao, Jing; Zheng, Qiufan; Su, Yanhong; Shu, Ditian; Zhang, Yue; Yang, Wei; Lei, Xuefen; Cai, Yuchen; Xue, Cong; An, Xin; Shi, Yanxia

Journal: CANCER COMMUNICATIONS. 2026; Vol. 46, Issue , pp. -. DOI: 10.34133/cancomm.0025

2
First-Line Tislelizumab Combined with Bevacizumab and CAPOX for Metastatic Gastroesophageal Adenocarcinoma with Low Programmed Death-Ligand 1 Expressio

Author:Jia, Ru; Wang, Yan-Rong; Liu, Fang-Fang; Ma, Yue; Si, Hai-Yan; Han, Lu; Gou, Miao-Miao; Tan, Zhao-Li; Zhang, Nan; Deng, Guo-Chao; Fan, Meng-Jiao; Shi, Yue; Zhang, Yao-Yue; Jia, Yu-Shan; Xu, Jun-Nan; Su, Xiao-Xing; Han, Quan-Li; Wang, Zhi-Kuan; Dai, Guang-Hai

Journal: CANCER COMMUNICATIONS. 2026; Vol. 46, Issue , pp. -. DOI: 10.34133/cancomm.0024

3
Harnessing the Power of CAR-NK Cells for Solid Tumors: Challenges, Innovations, and Future Frontiers in Immunotherap

Author:An, Mengchao; Yan, Jiayao; Liu, Baorui; Liu, Qin

Journal: CANCER COMMUNICATIONS. 2026; Vol. 46, Issue , pp. -. DOI: 10.34133/cancomm.0023

4
The Roles of Protein S-Palmitoylation in Cancers: From Dynamic Modulation to Therapeutic Potentia

Author:Zheng, Haonan; Sun, Xiaoyu; Gao, Yang; Wang, Qinbiao; Wang, Jiaqi; Wei, Minjie; Tang, Yu; He, Miao

Journal: CANCER COMMUNICATIONS. 2026; Vol. 46, Issue , pp. -. DOI: 10.34133/cancomm.0017

5
TOPK Suppresses the CD8+ T Cell Antitumor Immunity via Modulation of IRF5 Expressio

Author:Zang, Nianke; Gan, Jinfeng; Chen, Ye; Huang, Zheng; Xie, Chichu; Dang, Junlong; Huang, Changyuan; Yang, Linjie; Chen, Xuelian; Rong, Guangli; Sun, Jianbo; Shao, Yiming; Wang, Julie; Qi, Guangying; Liu, Yu; Zheng, Song Guo

Journal: CANCER COMMUNICATIONS. 2026; Vol. 46, Issue , pp. -. DOI: 10.34133/cancomm.0021

6
Vebreltinib for Previously Treated Astrocytoma, IDH-Mutant, Grade 4, and Glioblastoma, IDH Wild-Type with PTPRZ1-MET Fusion Gene: A Multicenter, Phase III Randomized, Open-Label Tria

Author:Bao, Zhaoshi; Xue, Yake; Liu, Yanhui; Li, Shouwei; Wang, Liang; Qu, Yan; Mou, Yonggao; Yu, Rutong; Wu, Jinsong; Yao, Yu; Shu, Kai; Hu, Guangyuan; Cai, Linbo; Li, Wenbin; Qiu, Xiaoguang; Li, Yunqian; Zhang, Lei; Qi, Songtao; Ji, Ying; Ma, Chunxiao; Ma, Wenbin; Li, Gang; Tao, Rongjie; Sun, Chongran; Chen, Ligang; Lv, Sheng-Qing; Liang, Peng; Pan, Hao; Peter, Woo Yat Ming; Danny, Chan Tat Ming; Mao, Qing; Wei, Xinting; Jiang, Tao

Journal: CANCER COMMUNICATIONS. 2026; Vol. 46, Issue , pp. -. DOI: 10.34133/cancomm.0019

7
Ectopic CD11c Drives SMAD3-Mediated Aberrant Antigen Presentation and Epithelial-Mesenchymal Transition in Esophageal Squamous Cell Carcinom

Author:Liao, Han; Zhao, Xuan; Chen, Liping; Liu, Qingyi; Li, Chenying; Li, Kai; Xi, Yiyi; Shen, Yanrong; Tan, Wen; Wu, Chen; Lin, Dongxin

Journal: CANCER COMMUNICATIONS. 2026; Vol. 46, Issue , pp. -. DOI: 10.34133/cancomm.0014

8
WTAP-Mediated Glutaminase Splicing Bias Suppresses Ferroptosis in Hepatocellular Carcinom

Author:Zhu, Can; Wu, Ke; Wu, Tong; Ma, Jun; Ding, Bo; Jiang, Nan; Du, Keyi; Ju, Guomin; Xie, Haiyang; Peng, Chuanhui; Wu, Jian; Zheng, Shusen

Journal: CANCER COMMUNICATIONS. 2026; Vol. 46, Issue , pp. -. DOI: 10.34133/cancomm.0005

9
TIMELESS Promotes LUAD Growth via Suppressing Transferrin-Mediated Ferroptosis and Reprograms the Tumor Microenvironment against Anti-PD-1 Immunotherap

Author:Hu, Chenchen; Hu, Feiming; Shao, Changjian; He, Yuanli; Su, Liping; Shi, Daimei; Yu, Lingying; Sun, Yuanjie; Wang, Jing; Zhang, Xiyang; Duan, Hongtao; Zhang, Junqi; Sun, Yubo; Jiang, Dongbo; Yan, Xiaolong; Yang, Shuya; Yang, Kun

Journal: CANCER COMMUNICATIONS. 2026; Vol. 46, Issue , pp. -. DOI: 10.34133/cancomm.0009

10
Tumor Microenvironment Onmyoji: Cytokines with Dual Protumor and Antitumor Role

Author:Wang, Yaxuan; Lin, Anqi; Liu, Zaoqu; Cheng, Quan; Zhang, Jian; Luo, Peng

Journal: CANCER COMMUNICATIONS. 2026; Vol. 46, Issue , pp. -. DOI: 10.34133/cancomm.0008


在线咨询

Cancer Communications

国际简称:CANCER COMMUN参考译名:癌症通讯

年发文量:49 CiteScore:40.3 是否预警:否 Gold OA文章占比:98.61% 研究类文章占比:73.47%

杂志社联系方式:111 RIVER ST, HOBOKEN, USA, NJ, 07030-5774

Cancer Communications